AI-designed drugs reach late-stage trials as Insilico's rentosertib recruits Phase 3
nathanbenaich · x · 2026-10-08
Nathan Benaich notes AI-assisted drug discovery is reaching late-stage clinical development: Generate Biomedicines' gb-0895, Enveda's env-294 for eczema and asthma (Phase 2a), and Insilico Medicine's rentosertib are actively recruiting Phase 3 patients.
He cautions that human trials will determine whether these medicines are safe and effective — but the density of late-stage pipelines marks AI drug discovery's shift from proof-of-concept to real validation.
More from Research
- Medical AI benchmark builder: his first ECG dataset had answers printed on images — MaziyarPanahi · 2026-10-08
- Learned latent dynamics roll forward from few observations to recover hopper state with uncertainty — hisspikeness · 2026-10-08
- Adding a pixel-reconstruction loss makes latents unable to decode hopper state — hisspikeness · 2026-10-08
- New theory shows SSL separates stochastic signals from nuisance via MI maximization plus distribution matching — hisspikeness · 2026-10-08
- The conundrum of latent prediction: signals themselves are stochastic, so what to keep? — hisspikeness · 2026-10-08
- Hippocampal cognitive maps support language learning, not just spatial navigation — abenitezburraco · 2026-10-08